R&D channel feed – Endpoints News

R&D channel feed

Oculis says its eye drops passed an early PhIII test. Researchers have to repeat it to win approval

3 years ago

Alnylam updates its pitch for expanded Onpattro label with 18-month PhIII data

3 years ago

Alexion touts early 'proof-of-concept' data for Neurimmune antibody in ATTR cardiomyopathy

3 years ago

First-of-its-kind gene therapy approved for healing wounds in “butterfly children”

3 years ago

Comanche lines up trial for preeclampsia siRNA with Moderna, Medicines Company vets and GV backing

3 years ago

In first look at mRNA protein replacement, Moderna touts early signals of promise for rare metabolic therapy

3 years ago

South Korean biopharma sees way forward after PhIII eye disease trial failure

3 years ago

After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline

3 years ago

Patient who received custom gene therapy likely died from immune reaction, not CRISPR, paper says

3 years ago

Updated: FDA panel backs Pfizer's RSV maternal vaccine, despite debate over safety

3 years ago

In a new look at Novo's Wegovy data, researchers spell out weight loss for teens

3 years ago

EyePoint sells remaining rights to eye implant, pivots to tackle anti-VEGFs

3 years ago

Intercept's NASH hopeful gets preliminary thumbs down in FDA briefing docs

3 years ago

PTC claims PhIII win in rare genetic disease

3 years ago

X4 touts more positive PhIII data for its WHIM syndrome treatment

3 years ago

Roche touts PhII win for BTK inhibitor in multiple sclerosis as PhIII showdown with Sanofi, Merck KGaA, Novartis looms

3 years ago

Viking claims NASH win after meeting primary endpoint in PhIIb study

3 years ago

#trekfortomorrow #3: How to survive the rigors of the Pacific Crest Trail and a career in cancer research

3 years ago

$97M gene therapy consortium aims to give companies and rare disease families a ‘north star’

3 years ago

Peter Hecht has a new syndicate, $81M in backing and a fresh shot at glory as his last start-up sputters out

3 years ago

Astellas, Sony partner up for antibody-drug conjugate platform to create 'better performing' drugs

3 years ago

Families raised millions and handed rare disease therapies off to biotechs. But companies have backed out

3 years ago

Dermavant's Vtama works again in eczema as Roivant subsidiary seeks label expansion next year

3 years ago

Colombian man's genetics should have doomed him to Alzheimer's. Instead, a rare mutation offers clue to protection

3 years ago

First page Previous page 86 87 888990 91 92 Next page Last page